Crohn's Disease - KOL Insight

Explore current and emerging treatments for Crohn's disease, including TNF inhibitors, Entyvio, Stelara, Skyrizi, Rinvoq, Tremfya, Omvoh, Zeposia, and Velsipity. This comprehensive report offers an in-depth analysis of the efficacy, safety, and usability of these treatments, as well as insights into recent clinical trials that could shape future prescribing trends. Examine the impact of biosimilars and subcutaneous formulations on the market, offering a detailed look at how the treatment landscape for moderate-to-severe Crohn's disease is evolving. Gain valuable knowledge on physician and payer preferences, the competitive positioning of pipeline products, and the overall market trends influencing drug therapies for Crohn's disease.

Key brands covered in this report:

• Remicade (infliximab)
• Humira (adalimumab)
• Cimzia (certolizumab pegol)
• Entyvio (vedolizumab)
• Stelara (ustekinumab)
• Skyrizi (risankizumab)
• Rinvoq (upadacitinib)
• Tremfya (guselkumab)
• Omvoh (mirikizumab)
• Zeposia (ozanimod)
• Velsipity (etrasimod)

Key questions answered:

• Which CD therapies are preferred for different patient segments and lines of therapy?
• How do medical professionals perceive the efficacy, tolerability, and ease of administration of these therapies?
• Which recent clinical trials could significantly influence CD prescribing trends?
• How might the use of current and pipeline drugs change in the future?
• What must pipeline products demonstrate to compete with existing CD therapies?
• Which pipeline products are most promising and how might they impact the market?
• How will the CD treatment landscape evolve for different patient segments and therapy lines?

Companies:

AbbVie, Lilly, AstraZeneca, UCB, Pfizer, Merck Sharp & Dohme, Bristol Myers Squibb, Takeda, Johnson & Johnson.